Slingshot members are tracking this event:

Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GLPG Community voting in process

Additional Information

Additional Relevant Details FLORA is a randomized, double-blind, placebo-controlled study investigating a once daily oral dose of GLPG1690 administered for 12 weeks in 24 IPF patients. Primary objectives of the study are to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG1690 in an IPF patient population. Target engagement will be measured by LPA in plasma and bronchoalveolar lavage fluid, both at baseline and through twelve weeks of treatment. Secondary objectives include the evaluation of lung function, changes in disease biomarkers and quality of life. Galapagos expects to complete patient recruitment before end 2016, and to report topline results in Q2 2017. GLPG1690 is a small molecule inhibitor of autotaxin and fully proprietary to Galapagos.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Glpg1690, Idiopathic Pulmonary Fibrosis, Phase 2a, Flora, Flora Is A Randomized, Autotaxin Target